WALTHAM, MA--(Marketwire - June 09, 2008) - EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the appointment of Praveen Tyle, Ph.D., as a member of its Board of Directors. Dr. Tyle is currently Chief Scientific Officer, and Corporate Vice President, Research & Development at Bausch & Lomb, a global healthcare company dedicated to perfecting vision and enhancing life for consumers around the world.
